Inotiv Inc. Overview

Inotiv Inc., a prominent contract research organization, provides essential research and development resources to pharmaceutical, medical device, and biotechnology companies globally. Based in West Lafayette, United States, Inotiv has been a key player in the Life Sciences Tools & Services sector since its public debut on Nasdaq in November 1997.

Recent Financial Performance

As of August 14, 2025, Inotiv’s stock closed at $1.89. This figure is notably lower than the company’s 52-week high of $6.48, recorded on December 15, 2024. Conversely, the stock reached its 52-week low of $1.15 on April 9, 2025. The company’s market capitalization currently stands at $63,210,000 USD.

Financial Ratios

Inotiv’s financial health is reflected in its price-to-earnings (P/E) ratio, which is currently at -0.617. This negative P/E ratio indicates that the company is not currently generating profits, a situation that may be of concern to investors.

Industry Role

Inotiv Inc. plays a crucial role in the healthcare sector by offering a range of research and development services. These services are vital for pharmaceutical, medical device, and biotechnology companies seeking to innovate and bring new products to market. By providing these resources, Inotiv supports the advancement of healthcare solutions worldwide.

Conclusion

Inotiv Inc. continues to be a significant entity in the Life Sciences Tools & Services industry, despite recent financial challenges. Its role in supporting the research and development efforts of various healthcare companies underscores its importance in the sector. Investors and industry observers will likely keep a close watch on the company’s financial performance and strategic initiatives moving forward.